A Look at Biogen’s Alzheimer’s Disease Portfolio



Biogen and Eisai collaboration

Biogen (BIIB) and Eisai have collaborated to jointly develop and commercialize therapies for Alzheimer’s disease. Eisai took the lead in co-developing a BACE inhibitor, elenbecestat, and an anti-amyloid beta protofibril antibody, BAN2401.

Biogen took the lead in co-development of an anti-amyloid beta antibody, aducanumab. Biogen and Eisai expect to jointly promote the drugs in major markets worldwide.

Article continues below advertisement

Alzheimer’s pipeline update

In July, Biogen (BIIB) and Eisai presented results of a Phase 2 clinical trial of their investigational BACE inhibitor elenbecestat at the AAIC (Alzheimer’s Association International Conference), which was held in Chicago. Biogen and Eisai conducted the Phase 2 study 202 trial to evaluate the safety and tolerability of elenbecestat, compared to placebo in the treatment of individuals with MCI (mild cognitive impairment) or dementia due to Alzheimer’s disease.

In the clinical trial, elenbecestat demonstrated its potential to slow the decline of cognitive functions in individuals with MCI due to Alzheimer’s disease. To learn more about the clinical trial results, please refer to Biogen’s July 25 press release.

At the AAIC conference, Eisai and Biogen (BIIB) also presented results of the Phase 2 study 201 trial of BAN2401. This study evaluated the safety and efficacy of the drug in individuals with MCI due to Alzheimer’s disease.

In the clinical trial, BAN2401 demonstrated significant slowing of the decline of cognitive functions compared to placebo. Also, BAN2401 showed acceptable tolerability in Alzheimer’s disease patients. Details of these results were also reported in Biogen’s July 25 press release.

In August, Biogen and Eisai announced the results of the ongoing long-term extension Phase 1b trial of aducanumab. In the Phase 1b trial, Eisai and Biogen are evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of aducanumab for the treatment of individuals with prodromal Alzheimer’s disease. The data from the long-term extension trial remained consistent with the data from the prior studies.


More From Market Realist